Our Clinical Trials Overview
Physician-led research in the greater Houston area. Participation is voluntary, and every study is reviewed by an independent Institutional Review Board before it opens.
Blood cancers 2 studies
Multiple Myeloma
Continuous low-dose subcutaneous therapy study
- Adults with multiple myeloma
- Investigational continuous subcutaneous dosing
- Close monitoring in a dedicated Phase 1 unit
Newly Diagnosed Multiple Myeloma
Biosimilar comparison study, transplant-ineligible
- Newly diagnosed, not planning a stem-cell transplant
- Subcutaneous daratumumab-based regimen
- Investigational product compared with the reference medicine
Solid tumors 9 studies
Liver Cancer (HCC)
First-line immunotherapy combination study
- Hepatocellular carcinoma that cannot be surgically removed
- No prior systemic treatment for advanced disease
- Ipilimumab + nivolumab: investigational vs. reference product
Esophageal & GE Junction Cancer
Immunotherapy after chemoradiation and surgery
- Stage II–III esophageal or gastroesophageal junction cancer
- Completed chemoradiation, then complete surgical removal
- Residual cancer found in the surgical specimen
- Surgery within the past 4–16 weeks
Melanoma
Immunotherapy after complete surgical removal
- Stage IIB, IIC, III or IV melanoma, fully removed with clear margins
- Surgery and sentinel lymph node check within the past 12 weeks
- No treatment for melanoma other than surgery
Urothelial Cancer (Bladder, Ureter, Renal Pelvis)
Immunotherapy after radical surgery
- Muscle-invasive urothelial cancer removed by radical surgery within the past 120 days
- High risk of the cancer returning, based on pathology
- Not receiving cisplatin chemotherapy after surgery — ineligible or declined
Bladder Cancer (MIBC)
Adjuvant antibody-drug conjugate study after surgery
- Muscle-invasive urothelial cancer, surgically removed
- High risk of recurrence without complete pathological response
- Antibody-drug conjugate plus immunotherapy
Metastatic Colorectal Cancer
Previously treated, microsatellite-stable (MSS)
- Metastatic colorectal cancer, MSS
- Prior treatment for metastatic disease
- Investigational therapy vs. regorafenib or fruquintinib
RAS G12D Colorectal Cancer
First-line targeted therapy plus chemotherapy
- Metastatic colorectal cancer with a RAS G12D mutation
- No prior systemic therapy for metastatic disease
- Targeted therapy added to standard chemotherapy
Prostate Cancer (mHSPC)
Double-blind add-on to hormone therapy
- Metastatic hormone-sensitive prostate cancer
- Prior docetaxel or PSMA-directed lutetium therapy
- Investigational agent added to an androgen receptor pathway inhibitor
Advanced Breast Cancer
Ovarian suppression study, premenopausal
- HR+ / HER2- advanced or metastatic breast cancer
- Premenopausal
- 3-monthly goserelin injection — NCT07310420
Rheumatology & immunology 1 study
Cutaneous Lupus
Oral investigational therapy vs. placebo
- Active subacute or chronic cutaneous lupus (SCLE / CCLE)
- Oral study medicine taken at home
- Randomized, double-blind, placebo-controlled
Programs in development 3 studies
Respiratory
Asthma and COPD trials
- Moderate-to-severe asthma
- Severe eosinophilic asthma
- COPD with a history of flare-ups
Neuroscience
Mood and neurodegenerative disease trials
- Major depressive disorder, incl. treatment-resistant
- Bipolar disorder
- Alzheimer's disease · Parkinson's disease
Metabolic & Obesity
GLP-1 maintenance trial
- BMI 25 kg/m² or higher
- Currently on a weekly GLP-1 medicine with ≥10% weight loss
- Stable weight and GI tolerability